• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals

By: AscellaHealth, LLC via GlobeNewswire
January 09, 2025 at 10:00 AM EST

PipelineDigest_2024Q4_Article_MAR-152-010325.1

BERWYN, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today launched its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive digital resource for information on new, pending and upcoming specialty and rare disease drug launches, biosimilars and cell and gene therapies (CGTs). This complimentary quarterly publication provides stakeholders and decision-makers with crucial, timely updates to support the needs of the specialty drug market.

“Specialty pharmaceutical product approvals are advancing at an unprecedented rate, underscoring the increasing wave of innovation across the healthcare sector,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “As the demand for novel therapies to address rare and complex conditions continues to increase, the AscellaHealth Specialty & Rare Pipeline Digest becomes a crucial resource for industry leaders seeking reliable, actionable information that supports effective go-to-market strategic planning and successful product commercialization. Our goal is to collaborate with manufacturers, payers and providers to enhance the affordability and distribution of these transformative therapies.”

The Q4 data highlights sustained growth in key specialty sectors, marked by notable increases in SP drug approvals and biosimilar launches. These valuable insights provide decision-makers with the information, data and expertise needed to develop and execute successful market access strategies.

“Effective product management and informed decision-making rely on dependable industry insights and precise data,” says Dea Belazi, CEO, AscellaHealth. “By offering this complimentary digest, we reaffirm our commitment to supporting our industry partners and delivering meaningful value across the specialty pharmaceutical landscape."

This digital resource complements the findings outlined in AscellaHealth’s 2024 Specialty Pharmaceutical Review: Key Highlights and Industry Trends, highlighting the industry’s rapid advancement driven by breakthroughs in AI, machine learning and advanced data analytics. Looking ahead, AscellaHealth anticipates continued industry progress and the accelerated development of specialty therapies, leading to improved therapeutic outcomes for rare diseases and more focused patient-centered care.

Access the latest Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC
AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6f4565fd-0b87-4d06-a1bf-2a364346df26

This press release was published by a CLEAR® Verified individual.


Media:

Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54

Primary Logo

More News

View More
The Bottom Is in for Kohl’s, But Let the Share Price Come to You
Today 9:53 EDT
Via MarketBeat
Topics Economy
Tickers KSS
Coca-Cola Q2 Margins Rise; Is KO Stock Undervalued?
Today 9:11 EDT
Via MarketBeat
Topics Economy
Tickers KO
2 Chinese Stocks That Could Leave U.S. Tech in the Dust
Today 8:25 EDT
Via MarketBeat
Topics ETFs Stocks
Tickers BABA KWEB MCHI NVDA
Why Meta’s AI Titan Clusters Are a Game-Changer for Broadcom
Today 7:26 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AVGO GOOG META NVDA
4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise
Today 7:13 EDT
Via MarketBeat
Tickers JNJ JPM LEVI NFLX
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap